Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171234 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| SCHEMBL2495325 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| SCHEMBL9343685 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL15329139 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL5105833 | 0.98 | ALDH1A1 (0.54) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| Acetic Acid SCHEMBL11614488 | 0.94 | ALDH1A1 (0.51) | ALDH1A1CHRNA7GAACHRM2CHRM1 | |
| SCHEMBL4339192 | 0.88 | CHRM2 (0.42) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| SCHEMBL4762996 | 0.88 | CHRM2 (0.42) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| SCHEMBL7493133 | 0.88 | CHRM2 (0.42) | ALDH1A1CHRNA7CHRM2CHRM1MEN1 | |
| Acetonitrile SCHEMBL28099504 | 0.88 | CHRM2 (0.49) | ALDH1A1CHRNA7GAACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854720-A1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER INC. (US) | 1998-07-29 | — | — | EP | claimed |
| WO-1997013514-A1 | NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY | PFIZER INC. (US) | 1997-04-17 | — | — | WO | claimed |
| EP-0708771-A1 | BENZYLOXYQUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1995002595-A1 | BENZYLOXYQUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | claimed |
| US-4321172-A | Organic polymers with acylurea repeating units having tertiary amino groups pendant therefrom and cathodic electrocoating of said polymers | DESOTO, INC. (US) | 1982-03-23 | — | — | US | claimed |
| US-4146628-A | NO SIDE EFFECTS | OPPENHEIMER EDNA | 1979-03-27 | — | — | US | claimed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | SIRONAX BEIJING CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| CN-119866332-A | Iron death inhibitor-phenoxazine acetamides | 维泰瑞隆（北京）生物科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2025077825-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIO-PULMONARY DISORDERS | FAUNA BIO INCORPORATED (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| EP-0513974-A1 | Novel benzo-fused lactams that promote the release of growth hormone | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0438311-A2 | Di- and tripeptide renin inhibitors | MERCK & CO. INC. (US) | 1991-07-24 | — | — | EP | disclosed |
| US-4321172-A | Organic polymers with acylurea repeating units having tertiary amino groups pendant therefrom and cathodic electrocoating of said polymers | DESOTO, INC. (US) | 1982-03-23 | — | — | US | disclosed |
| US-4292190-A | ANTIFREEZES FOR COOLING SYSTEMS OF INTERNAL COMBUSTION ENGINES | BASF WYANDOTTE CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
| US-4146628-A | NO SIDE EFFECTS | OPPENHEIMER EDNA | 1979-03-27 | — | — | US | disclosed |
| US-4146628-A | NO SIDE EFFECTS | OPPENHEIMER EDNA | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | AIFM2, GPX4, FECH | ALDH1A1 1064/4885CHRNA7 4853/4885GAA 4048/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | ALDH1A1 4385/4885CHRNA7 4298/4885GAA 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.